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Review
CSF-1 as a Regulator of Macrophage Activation 
and Immune Responses
MATTHEW J. SWEET* and DAVID A. HUME
M. Sweet and D. A. Hume: CSF-1 as Immunological Regulator
CRC for Chronic Inflammatory Diseases, Institute for Molecular Bioscience and Departments of Microbiology/Parasitology 
and Biochemistry, University of Queensland, Qld 4072, Australia
Abstract. Macrophage activation is a key determinant of susceptibility and pathology in a variety of inflammatory
diseases. The extent of macrophage activation is tightly regulated by a number of pro-inflammatory cytokines
(e.g. IFN-γ, IL-2, GM-CSF, IL-3) and anti-inflammatory cytokines (e.g. IL-4, IL-10, TGF-β). Macrophage
colony-stimulating factor (CSF-1/M-CSF) is a key differentiation, growth and survival factor for monocytes/mac-
rophages and osteoclasts. The role of this factor in regulating macrophage activation is often overlooked. This
review will summarize our current understanding of the effects of CSF-1 on the activation state of mature
macrophages and its role in regulating immune responses.
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Introduction
The production of circulating monocytes and tissue
macrophages from the bone marrow is dependent on
colony-stimulating factor 1 (CSF-1). This is high-
lighted by the gross deficiencies in macrophage devel-
opment and numbers that occur in the op/op mouse,
which has a natural inactivating mutation in the CSF-1
gene (for review see84), and by the demonstration that
administration of CSF-1 to mice caused a 10-fold
increase in blood monocyte numbers and increased
macrophage numbers in the liver, spleen and peritoneal
cavity41.
Via alternative splicing, post-translational modifica-
tions and proteolytic processing, CSF-1 is produced in
multiple forms; a secreted homodimeric glycoprotein,
a secreted proteoglycan and a membrane-bound glyco-
protein73, 84. The CSF-1 receptor (CSF-1R), encoded by
the c-fms protooncogene, is a type III receptor tyrosine
kinase with structural similarity to c-kit and the platelet-
-derived growth factor receptor and the fms-like recep-
tors flk, and flt 1, 2 and 3. Mice with a targeted disrup-
tion of the c-fms gene are essentially a phenocopy of
the op/op mouse, indicating that all of the actions of
CSF-1 are mediated by the CSF-1R18. Ligand binding
to the CSF-1R initiates receptor dimerization, auto-
Abbreviations used: BMM – bone marrow-derived macrophage, CpG DNA – bacterial CpG-containing DNA, CSF-1 – colony-stimu-
lating factor 1, CSF-1R – CSF-1 receptor, EBV – Epstein-Barr virus, HIV-1 – human immunodeficiency virus type 1, IDO – indoleamine
2,3-dioxygenase, IL – interleukin, LPS – lipopolysaccharide, MMP – matrix metalloproteinase, RA – rheumatoid arthritis, TLR – Toll-like
receptor, TNF – tumor necrosis factor.
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phosphorylation, and activation of multiple signalling
cascades including the mitogen-activated protein kinase
and P-I-3 kinase/Akt pathways21, 35.
Although relatively few studies have addressed the
biological roles of the different CSF-1 isoforms, it is
likely that they have distinct functions in vivo. For
example, the proteoglycan form is localized to specific
types of extracellular matrix which might enable spe-
cialized functions such as regulation of bone homeos-
tasis68. Daily administration of soluble recombinant
CSF-1 to the op/op mouse from day 3 of life was able
to correct some but not all of the deficiencies in mac-
rophage numbers in different tissues13. This supports
the argument that the full biological activity of CSF-1
requires all isoforms and not just soluble circulating
CSF-1, although it is also possible that pre-natal ab-
sence of CSF-1 has effects that cannot be subsequently
restored by exogenous CSF-1. The gene regulatory ele-
ments that are sufficient to reconstitute normal CSF-1
expression in vivo have been defined77. Transgenic ex-
pression on the op/op background of cDNAs encoding
the secreted, proteoglycan or membrane-bound iso-
forms under the control of these elements should there-
fore provide clear evidence for any isoform-specific
functions.
Regardless of the functions of the different iso-
forms, it is clear that CSF-1 is abundantly present in
vivo. The major source of circulating CSF-1 is thought
to be endothelial cells that line blood vessels76, but
a range of other cell types, including fibroblasts, osteo-
blasts, monocytes, B cells, T cells and bone marrow
stromal cells also produce CSF-1. In mice, CSF-1 le-
vels are in the order of tens of nanograms per millilitre
in the circulation and tens of picograms per milligram
in a variety of tissues including liver, lung, spleen, kid-
ney, intestine and heart75. CSF-1 levels are dramatically
increased upon challenge with lipopolysaccharide
(LPS)75 or with infectious agents such as Listeria mono-
cytogenes15, 32 and Candida albicans14. In humans,
a similar situation is apparent; CSF-1 levels were en-
hanced in patients with sepsis29, and LPS administration
to cancer patients increased CSF-1 levels23. These ob-
servations would suggest that CSF-1 is likely to regu-
late immune responses to infection in both mice and
humans.
Macrophage-Priming by CSF-1
The requirement for the CSF-1/CSF-1R system in
macrophage development makes interpretation of in
vivo studies aimed at addressing the role of CSF-1 in
immunological responses difficult, since modulation of
CSF-1 action affects both monocyte/macrophage pro-
duction and survival, as well as mature macrophage
functions. Additionally, CSF-1 is required for the main-
tenance of protein synthesis. JESSUP et al.43 showed that
CSF-1 greatly increased acetylated low-density lipopro-
tein uptake and foam cell formation, but this was en-
tirely attributable to an increase in cell size; no effect
was apparent when these parameters were assessed on
a per microgram protein basis. This absolute require-
ment on CSF-1 for normal macrophage function raises
an important issue with regard to the many in vitro
studies that are performed on this cell type. Since it is
normally present in vivo and because its absence has
gross effects on normal cellular functions, CSF-1
should be present in culture medium during in vitro
studies on macrophage function. This is often not the
case, particularly in immunological studies.
A role for CSF-1 in regulating macrophage activa-
tion and inflammation is supported by in vitro studies
in which CSF-1 enhanced macrophage phagocytic ac-
tivity against Listeria monocytogenes16, microbicidal ac-
tion against Leishmania mexicana40, Candida albicans47
and Aspergillus fumigatus74 and primed tumoricidal ac-
tivity upon triggering with activating agents66, 79, 80. In
other studies, CSF-1 did not enhance the ability of mac-
rophages to kill intracellular organsims, including
Leishmania major6, Mycobacterium tuberculosis19 and
Listeria monocytogenes20. The basis for this inconsist-
ency is unclear.
In contrast to in vitro studies, in vivo studies strong-
ly support a role for CSF-1 in regulating primary im-
mune responses to infection. For example, mice chall-
enged with Listeria monocytogenes had an increased
bacterial load following administration of an anti-CSF-1
antibody at the time of challenge32 and CSF-1 trans-
genic mice were more resistant to Listeria monocy-
togenes than wild-type controls8. CSF-1 administration
also had protective effects for the host against challenge
with Listeria monocytogenes49 and Candida albicans14.
As well as enhancing the ability of macrophages to
destroy invading pathogens directly, CSF-1 is also
a potent regulator of monokine production that regu-
lates the magnitude of the inflammatory response. CSF-1
alone triggered production of mRNAs for interleukin
(IL)-6, granulocyte macrophage (GM)-CSF, IL-1α and
IL-1β in murine resident peritoneal macrophages25, 45.
In other studies with different macrophage populations,
CSF-1 alone did not trigger pro-inflammatory cytokine
production, but instead acted as a potent priming signal
for a subsequent activation stimulus. Pre-treatment of
thioglycollate-elicited peritoneal macrophages or bone
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marrow-derived macrophages (BMM) with CSF-1-en-
hanced production of key pro-inflammatory cytokines,
including IL-6, IL-12 and tumor necrosis factor (TNF)-α,
upon triggering with LPS26, 45, 46, 86, TNF-α26 or extrac-
ellular matrix proteins51, 52. Similar priming effects of
CSF-1 have been reported for human monocytes3, 80, 98.
These in vitro studies correlate with in vivo studies in
which the op/op mouse was resistant to the toxic effects
of LPS87, 100, although the interpretation of this data is
somewhat compromized by the defects in macrophage
development in the op/op mouse.
Interestingly, the ability of CSF-1 to prime macro-
phage activation is dependent upon the nature of the
activating stimulus. Whereas CSF-1 synergized with
LPS for pro-inflammatory cytokine production from
BMM, it suppressed these responses when the activat-
ing signal was bacterial CpG-containing DNA (CpG
DNA) and had no effect when the stimulus was bac-
terial lipopeptide86. Hence, the role of CSF-1 may de-
pend upon the type of infectious challenge. In Gram-
-negative infections where LPS will be detected, CSF-1
may act as a potent priming signal for macrophage ac-
tivation, whilst in a Gram-positive infection CSF-1 may
not be as critical in regulating macrophage function.
The differential effects of CSF-1 on responses to
different activating signals is, in part, mediated by se-
lective effects of CSF-1 on expression of Toll-like re-
ceptors (TLRs)86, which are required for signaling in
response to microbial products89. Whereas CSF-1 did
not regulate expression of a variety of TLR members,
including TLR3, 4, 5 and 7, expression of TLR9,
which is required for responses to CpG DNA, was
down-regulated by CSF-1. Levels of TLR2 and 6 mRNA,
encoding receptors for Gram-positive components, were
also moderately suppressed by CSF-1 (unpublished data
and 86).
The biological significance of the potent inhibitory
effect of CSF-1 on TLR9 expression and responses to
CpG DNA is not clear, but others have also reported
that CSF-1 can in some cases inhibit macrophage acti-
vation. For example, CSF-1 pretreatment inhibited the
macrophage respiratory burst when zymosan, a TLR2/
/TLR6 agonist69, was used as the triggering signal70.
Hence, CSF-1 may have dual roles in responses to in-
fection; as a positive regulator of macrophage activa-
tion when extreme danger signals such as LPS are de-
tected and to prevent excessive macrophage activation
when less hazardous products such as CpG DNA and
zymosan are encountered.
Mechanisms of CSF-1-Mediated Priming
of Cytokine Production
In human monocytes/macrophages, the mechanisms
by which CSF-1 primes activation have not been exten-
sively studied. CSF-1 marginally increased expression
of CD14 on human monocytes and this may partially
account for increased sensitivity to LPS3. Whether
CSF-1 regulates LPS recognition in murine macro-
phages has not been adequately addressed, but CSF-1
did not regulate expression of the receptor for LPS,
TLR4 or early signaling events in response to maximal
LPS doses86. Instead, CSF-1 appears to prime murine
macrophage responses to LPS through a number of dis-
tinct mechanisms. The synergism between CSF-1 and
either LPS or TNF-α for IL-6 production, from resident
peritoneal macrophages was largely-mediated by CSF-
-1-stimulated autocrine GM-CSF production, since sy-
nergism was greatly reduced, although not abolished,
in GM-CSF-deficient mice26. The mechanism by which
CSF-1 augments IL-12 production is not known, but
may also involve autocrine GM-CSF, since this factor
synergises with LPS for IL-12 production (unpublished
data and 39). Another possibility is that synergy occurs
at the transcriptional level, since Ets-2, which binds to
and activates the IL-12 p40 promoter56, 57, is activated
in a sustained fashion in response to CSF-128. The
priming effect for TNF-α production is downstream of
mRNA regulation since CSF-1 enhanced LPS-induced
TNF-α secretion but not LPS-induced TNF-α mRNA
levels in BMM86. Since CSF-1 is known to increase
production of matrix metalloproteinase (MMP) 992, one
possibility is that CSF-1 also induces production of the
MMP-related protein TNF-α converting enzyme that is
required for cleavage of membrane-bound TNF-α60, 61.
CSF-1 as a Regulator of Leukocyte Recruitment
Apart from affecting macrophage activation, CSF-1
acts at multiple levels to regulate cellular recruitment,
a hallmark of inflammatory responses. Firstly, CSF-1
has pronounced effects on macrophage motility. Treat-
ment of the CSF-1-dependent murine macrophage cell
line BAC1.2F5 with CSF-1 rapidly triggered actin re-
organization, membrane ruffling and cell spreading2, 11.
Further, CSF-1 had chemokinetic and chemotactic ac-
tivity on human monocytes96, BAC1.2F5 cells99 and
myeloid progenitor cells-transfected with a c-fms ex-
pression plasmid71. Thus, the enhanced production of
CSF-1 during responses to infection may serve to re-
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cruit monocytes rapidly to the inflammatory site. Sec-
ondly, CSF-1 regulates expression of many genes that
encode mediators of adhesion and migration. These in-
clude the integrins, α4β1 and α5β182, urokinase plas-
minogen activator36, 83, plasminogen activator inhibi-
tors17, 36, 101 and MMP992. Finally, CSF-1 may enhance
chemokine production from monocytes/macrophages,
thereby allowing for recruitment of other effector cells;
CSF-1 increased IL-8 production from human mono-
cytes38, 90. The importance of CSF-1 for the recruitment
of monocytes during inflammatory responses has also
been documented in vivo. Blockade of CSF-1 action
suppressed monocyte recruitment during Listeria
monocytogenes infection31 and renal inflammation54.
CSF-1 Involvement in Viral Infections
Many viruses, including respiratory syncytial virus,
measles virus, dengue virus and HIV-1, replicate within
macrophages as a means of escaping immune detec-
tion, and in many cases CSF-1 regulates macrophage
function during viral infection. This is particularly true
for HIV-1, where CSF-1 is an important factor in the
HIV-1 replicative strategy. Firstly, HIV-1 replication
has been associated with increased CSF-1 production
in vivo30 and replication of HIV-1 within monocyte-
-derived macrophages triggered CSF-1 production33, 53.
Secondly, CSF-1 enhanced HIV-1 replication in mac-
rophages7, 44, possibly by regulating expression of the
HIV-1 co-receptor CCR597. Thus, HIV-1 appears spe-
cifically to induce CSF-1 production from macrophages
and this, in turn, enhances its ability to replicate within
this cell type. CSF-1/CSF-1 receptor antagonists may
therefore have therapeutic potential as agents to block
HIV-1 replication within macrophages.
Whilst CSF-1 is a positive regulator of HIV-1 repli-
cation, it may be protective to the host for other viral
pathogens. Intranasal administration of CSF-1 offered
almost complete, protection to BALB/c mice upon
challenge with otherwise lethal doses of Sendai virus59,
and CSF-1 treatment of macrophages in vitro induced
resistance to vesicular stomatitis virus55. Interestingly,
Epstein-Barr virus (EBV) encodes a protein, BARF1,
that bound to and neutralized CSF-185. Although the
biological consequences of this have not been ad-
dressed, one might predict that blockade of CSF-1 sig-
naling via BARF1 would provide a selective advantage
to EBV over the host. Indeed, there are reports of CSF-
-1R expression on B cells4, 91, which may be relevant
to EBV infection. Whilst some of the anti-viral actions
of CSF-1 may be attributed to production of type 1 and
type 2 interferons55, 59, one report demonstrated that
a CSF-1 expression construct, when administered with
a DNA vaccine, enhanced cytotoxic T lymphocyte re-
sponses50. Therefore, CSF-1 may also enhance the de-
velopment of antigen-specific anti-viral mechanisms.
Effects of CSF-1 on the Acquired Response
Whilst most of the studies described above indicate
that CSF-1 enhances macrophage activation and the in-
nate response, CSF-1 is actually immunosuppressive
for antigen-specific responses. T cell responses against
allogeneic cells were suppressed in the presence of
CSF-1-stimulated macrophages from tumor-bearing
hosts95, and CSF-1 suppressed MHC class II expression
in the placenta94. Other studies have substantiated this
immunosuppressive effect of CSF-1 in vitro62, 63, and
CSF-1 administration in vivo suppressed proliferation
of purified splenocytes to T cell mitogens22.
Apart from targeting MHC class II expression, the
immunosuppressive effect of CSF-1 may be dependent
on the enzyme indoleamine 2,3-dioxygenase (IDO),
which was induced in co-cultures of CSF-1-derived
macrophages and T cells64. IDO rapidly degrades tryp-
tophan, an amino acid that is essential for T cell pro-
liferation. Several studies have reported inducible ex-
pression of membrane-bound CSF-1 on T cells upon
activation34, 72, 88, 102. Given the inhibitory effects of
CSF-1 on T cell proliferation, inducible expression of
CSF-1 in T cells may provide a negative feedback
mechanism to arrest T cell proliferation via antigen-
-presenting cell-mediated tryptophan depletion. Despite
these studies, the relevance of CSF-1 as an immuno-
suppressive agent during antigen-specific responses to
infectious agents remains to be established. However,
CSF-1-mediated effects on T cell function may be rele-
vant to tolerance of the allogeneic fetus during preg-
nancy. IDO expression in the placenta is critical for
maternal T cell tolerance65, and the most dramatic regu-
lation of CSF-1 in vivo occurs during pregnancy where
uterine, but not circulating, CSF-1 levels increase 1000
fold5. Hence, CSF-1-induced IDO may contribute to the
maintenance of tolerance to the developing fetus.
CSF-1 and Chronic Inflammatory Responses
The involvement of macrophages in chronic inflam-
matory diseases such as rheumatoid arthritis (RA) is
well established and the effects of CSF-1 in such dis-
eases have also been studied. In collagen-induced arth-
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ritis, a mouse model of RA, administration of CSF-1
exacerbated disease severity whilst an anti-CSF-1 anti-
body reduced the severity of established arthritis12.
CSF-1 has also been implicated as a contributor to
disease severity in other arthritic models1, 9. Evidence
exists for CSF-1 involvement in RA itself; CSF-1
levels were elevated in RA patient sera48 and synovial
fluid27, and synovial fibroblasts from RA patients
produce CSF-181.
Apart from arthritic diseases, there is an extensive
literature on the contribution of CSF-1 to kidney dis-
ease. Macrophage accumulation is a predictor of renal
outcome in glomerulonephritis and correlates with kid-
ney dysfunction in humans67, and elevated levels of
renal CSF-1 are apparent in glomerulonephritis pa-
tients42. Other studies have also documented enhanced
CSF-1 levels in sera of patients with chronic renal dis-
ease58, 78. In experimental disease models, there is clear
evidence for the involvement of CSF-1 in directing ex-
cessive macrophage proliferation and tissue damage.
The severity of lupus nephritis in MRL-lpr mice corre-
lated with CSF-1 levels10, treatment with anti-CSF-1R
antibody reduced local macrophage proliferation during
experimentally induced renal inflammation54, and treat-
ment of mice with CSF-1 enhanced LPS-induced glome-
rular macrophage accumulation and proteinuria93.
Conclusion
Determination of the exact roles of CSF-1 during
immune responses has been difficult because of its ess-
ential role in the differentiation, proliferation and nor-
mal cellular function of macrophages. Nonetheless,
numerous studies have documented effects of CSF-1 on
macrophage activation in vitro and inflammatory re-
sponses in vivo. The fact that CSF-1 levels are elevated
during responses to infection in mice and humans
strongly supports the concept that this factor has key
immunoregulatory functions. As with other pro-inflam-
matory cytokines, CSF-1 exerts protective effects
against many infectious agents (with some notable ex-
ceptions), but elevated levels of CSF-1 may contribute
to pathology in both acute and chronic inflammatory
diseases. Hence, specific antagonists of CSF-1 action
may have therapeutic potential as a means of prevent-
ing pathology associated with excessive macrophage
accumulation and activation.
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